Phase 1 Recurrent Cancer Clinical Trials
6 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics US, Inc.375 enrolled21 locationsNCT03686124
Recruiting
Phase 1Phase 2
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 1Phase 2
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Refractory CancerRecurrent CancerChildhood Cancer+2 more
Australian & New Zealand Children's Haematology/Oncology Group90 enrolled14 locationsNCT06208657
Recruiting
Phase 1Phase 2
Personalized Neoantigen Peptide Vaccines for Solid Tumors
Solid TumorsAdvanced CancerRecurrent Cancer+2 more
Seqker Biosciences, Inc.10 enrolled2 locationsNCT07002203
Recruiting
Phase 1Phase 2
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics Biotechnologies GmbH145 enrolled24 locationsNCT05958121
Recruiting
Phase 1
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics Biotechnologies GmbH95 enrolled23 locationsNCT05359445